Furthermore, Kyeong et al assigned patients with BMs from breast cancer to three groups: Luminal (HR-positive and HER2-negative), HER2 (HER2-positive and HR-positive or HR-negative), and TNBC (HR-negative and HER2-negative). This evidence concerns the gene ERBB2 and breast cancer.